Understand the source comparison
Cancer Research Peptides 2026 Update: Compound Class Comparison
PD-1/PD-L1 Mimetics Checkpoint inhibition. Blocks T-cell exhaustion signaling Melanoma, triple-negative breast cancer, non-small cell lung cancer 8–14 hours (D-amino acid substitution + PEGylation) 18–35% ORR depending on tumor type Lower efficacy than full an
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PD-1/PD-L1 Mimetics
- Checkpoint inhibition. Blocks T-cell exhaustion signaling
- Melanoma, triple-negative breast cancer, non-small cell lung cancer
- 8–14 hours (D-amino acid substitution + PEGylation)
- 18–35% ORR depending on tumor type
- Lower efficacy than full antibodies in immunologically 'cold' tumors
- ADC Linker Peptides
- Tumor-specific cytotoxic payload delivery via cathepsin B cleavage
- HER2+ gastric cancer, EGFR+ non-small cell lung cancer, TROP2+ triple-negative breast cancer
- 48–72 hours in circulation; cleaves within 6–12 hours post-internalization
- 55–65% ORR in HER2+ and TROP2+ cohorts
- Requires antibody targeting. Not standalone therapy
- GLP-1/GIP Dual Agonists
- Metabolic reprogramming. Reduces tumor glucose uptake and IGF-1 signaling
- Pancreatic adenocarcinoma, colorectal cancer (metabolic syndrome patients)
- 5–7 days (long-acting formulations)
- 12–20% partial response; 40–50% stable disease at 12 weeks
- Mechanism incompletely understood; efficacy limited to metabolic tumor phenotypes
- Cyclic RGD Peptides
- Integrin αvβ3 antagonism. Blocks angiogenesis and tumor cell adhesion
- Glioblastoma, ovarian cancer
- 4–6 hours (cyclisation improves proteolytic resistance)
- Phase I/II data pending. Enrollment ongoing
- Poor CNS penetration limits glioblastoma efficacy